Ocean State Academy Learning Center Llc Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 1135 Mineral Spring Ave, North Providence, RI 02904 Phone: 401-351-0610 |
Jeffrey Borozny Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 610 Smithfield Rd, North Providence, RI 02904 Phone: 401-353-6300 |
Ms. Erin Manchester, OTRL Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 1190 Charles St Apt 33, North Providence, RI 02904 Phone: 401-523-6949 |
Ms. Jennifer Lynne Cote, OTR/L Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 200 High Service Ave, North Providence, RI 02904 Phone: 401-456-3000 |
Mrs. Sheri Ann Lough, OTRL Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 200 High Service Ave, North Providence, RI 02904 Phone: 401-456-3894 |
News Archive
A triple-punch of antibodies both prevented hepatitis C infection and wiped out the disease after it had established itself in laboratory mice, according to a study led by Princeton University researchers.
One million people across England and North Wales are now registered to book donation appointments online, making it one of the largest digital booking systems of any blood service in the world.
Meda has completed the acquisition of Alaven and has taken over its operations. The acquisition will benefit Meda both short term and long term. The acquisition will add the therapeutic focus to include both gastroenterology and women's health; areas that Meda operates in outside of the US. In addition, Alaven has a strategic OTC platform that accounts for approximately 25% of sales. Alaven will further diversify Meda's revenue base in the US, as well as serve as a platform for commercializing strategic pipeline opportunities.
Genentech, a member of the Roche Group, today announced that the SUMMACTA study met its primary endpoint, showing comparable efficacy (non-inferiority) of the subcutaneous (SC) formulation of ACTEMRA (tocilizumab) 162mg weekly compared to 8 mg/kg ACTEMRA intravenous (IV) formulation every four weeks.
› Verified 3 days ago